<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Techniques for endovenous laser ablation for the treatment of lower extremity chronic venous disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel M Ihnat, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H715136631"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endovenous laser ablation (EVLA) is a percutaneous technique that uses laser energy to ablate incompetent superficial veins. The axial veins are the primary target for this therapy and include the great saphenous vein (GSV), small saphenous vein (SSV), and accessory saphenous veins (ASVs). </p><p>Although vein ligation/stripping was once the standard for the management of lower extremity varicose veins and venous reflux, randomized trials have found that minimally invasive therapies (eg, thermal, non-thermal), including EVLA provide similar or improved clinical outcomes compared with GSV ligation and stripping [<a href="#rid1">1-3</a>]. No significant differences in measures of venous symptom severity (eg, Venous Clinical Severity Score (<a class="calc calc_professional" href="/z/d/html/13453.html" rel="external">calculator 1</a>), Aberdeen Varicose Vein Symptom Score) and quality-of-life scores (eg, Medical Outcomes Study Short Form-36) have been found at short-term (one to three months) [<a href="#rid2">2,4,5</a>] or longer-term (two- [<a href="#rid6">6</a>] and five-year) follow-up in comparisons of EVLA and GSV ligation versus vein ligation/stripping in several clinical trials [<a href="#rid7">7</a>]. Compared with other forms of venous ablation, a systematic review and meta-analysis suggested that the pooled success rate for EVLA at three years was significantly higher compared with radiofrequency ablation, vein excision, or sclerotherapy (94 versus 84, 77, and 78 percent, respectively) [<a href="#rid1">1</a>]. A more detailed comparison of EVLA with other vein ablation techniques is provided separately. (See  <a class="medical medical_review" href="/z/d/html/15233.html" rel="external">"Comparison of methods for endovenous ablation for chronic venous disease", section on 'Outcome comparisons'</a> and  <a class="medical medical_review" href="/z/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Endovenous versus surgical ablation'</a>.)</p><p>The indications, perioperative care, and outcomes of EVLA are reviewed. Alternative approaches to the treatment of chronic venous disease using other minimally invasive thermal and non-thermal techniques, and open surgery are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8203.html" rel="external">"Techniques for radiofrequency ablation for the treatment of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129600.html" rel="external">"Nonthermal, nontumescent ablation techniques for the treatment of lower extremity superficial venous insufficiency"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8206.html" rel="external">"Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8176.html" rel="external">"Laser and light therapy of lower extremity telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Surgical options'</a>.)</p><p></p><p class="headingAnchor" id="H2727472694"><span class="h1">ANATOMY</span></p><p class="headingAnchor" id="H4252836444"><span class="h2">Venous anatomy</span><span class="headingEndMark"> — </span>The veins of the lower extremity are divided into superficial, perforating, and deep veins  (<a class="graphic graphic_figure graphicRef55019 graphicRef52340" href="/z/d/graphic/55019.html" rel="external">figure 1A-B</a>). The superficial veins lie superficial to the muscle fascia. The perforating veins cross the fascia and connect the superficial veins to the deep veins that are located beneath the fascia. The deep veins are <strong>never</strong> treated with endovenous ablation therapies.</p><p>The major superficial veins of the lower extremity include the great and small saphenous veins. These and the accessory saphenous veins are collectively referred to as the axial or truncal veins. (See  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Superficial venous system (As)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The great saphenous vein (GSV) is one of the two main superficial veins in the lower extremity. It is the longest vein in the body and originates on the medial aspect of the dorsal foot. It crosses anterior to the medial malleolus and ascends along the medial aspect of the leg and thigh. Just below the inguinal ligament, it enters the fossa ovalis and terminates in the common femoral vein at the saphenofemoral junction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The small saphenous vein (SSV) originates laterally from the dorsal venous arch of the foot, crosses posterior to the lateral malleolus, and ascends in the posterior calf  (<a class="graphic graphic_figure graphicRef55019 graphicRef52340" href="/z/d/graphic/55019.html" rel="external">figure 1A-B</a>). In the upper calf, the SSV passes through the deep muscle fascia and terminates in the popliteal vein; however, the anatomy at the sapheno-popliteal junction is variable  (<a class="graphic graphic_figure graphicRef82053" href="/z/d/graphic/82053.html" rel="external">figure 2</a>) [<a href="#rid8">8-11</a>]. The SSV can join an intersaphenous vein that is a superficial cephalad extension in the posterior thigh (ie, vein of Giacomini), connect to both the popliteal vein and the posterior thigh vein, or join the popliteal vein with no major tributaries near the junction  (<a class="graphic graphic_figure graphicRef82053" href="/z/d/graphic/82053.html" rel="external">figure 2</a>). Anatomic variations in the SSV have implications for SSV ablation [<a href="#rid11">11</a>]. (See <a class="local">'Small saphenous vein'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The accessory saphenous veins (ASVs) are any of several venous segments that ascend parallel to the GSV. Anterior ASVs are located anteriorly and can be found in the thigh or leg  (<a class="graphic graphic_figure graphicRef55019 graphicRef52340" href="/z/d/graphic/55019.html" rel="external">figure 1A-B</a>) [<a href="#rid12">12</a>]. </p><p></p><p>The deep veins of the lower extremity are contained within the deep muscle compartments bounded by the muscle fascia  (<a class="graphic graphic_figure graphicRef75219" href="/z/d/graphic/75219.html" rel="external">figure 3</a>). (See  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Deep venous system (Ad)'</a>.)</p><p>Perforating veins are those veins that traverse the muscular fascia to connect superficial veins with the deep veins. They are located anteriorly, posteriorly, laterally, and medially in both the thigh and calf. (See  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders"</a> and  <a class="medical medical_review" href="/z/d/html/8177.html" rel="external">"Classification of lower extremity chronic venous disorders", section on 'Perforator veins (Ap)'</a>.)</p><p>In the lower extremity, normal flow in the perforating veins is from superficial to deep; however, in the foot the flow is from the deep to superficial. Many perforating veins demonstrate bidirectional flow. When the blood flow is reversed greater than 0.5 seconds, perforating veins are considered incompetent. The most clinically significant perforating veins connect the posterior arch vein to the posterior tibial vein. These veins, termed posterior tibial perforators, were formerly known as Cockett perforators.</p><p class="headingAnchor" id="H1547187799"><span class="h2">Saphenous nerve</span><span class="headingEndMark"> — </span>The saphenous nerve is the largest cutaneous branch of the femoral nerve. It lies near the superficial femoral artery in the thigh, exiting the adductor canal, traveling deep to the sartorius muscle  (<a class="graphic graphic_figure graphicRef66562 graphicRef52007" href="/z/d/graphic/66562.html" rel="external">figure 4A-B</a>). It typically becomes superficial after it emerges medially between the tendons of the sartorius and gracilis muscles at the knee and then travels adjacent to the GSV. The saphenous nerve provides sensory innervation to the medial aspect of the leg and foot. The saphenous nerve is adherent to the saphenous vein in the distal third of the calf [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2406014531"><span class="h2">Sural nerve</span><span class="headingEndMark"> — </span>Identiﬁcation of the relative anatomy of the sural nerve to the SSV is important for avoiding damage to the sural nerve during EVLA. </p><p>The sural nerve is a cutaneous nerve coursing along the SSV and traversing posterior to the lateral malleolus toward the fifth toe  (<a class="graphic graphic_figure graphicRef62917" href="/z/d/graphic/62917.html" rel="external">figure 5</a>). The sural nerve provides cutaneous innervation to the posterior-lateral calf and lateral foot. In an autopsy study, the sural nerve was separated from the SSV by the deep muscular fascia above the inferior border of the gastrocnemius muscle, but below the inferior border of the gastrocnemius muscle, the sural nerve perforated the deep fascia to run in close proximity to the SSV, where it can easily be injured [<a href="#rid14">14</a>]. The sural nerve can vary in its course from the usual anatomy in up to one-half of patients and can usually be identified using ultrasound [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H715136638"><span class="h1">INDICATIONS</span></p><p class="headingAnchor" id="H300731139"><span class="h2">Symptomatic superficial venous reflux</span><span class="headingEndMark"> — </span>The indications for EVLA are the same as for other vein ablation therapies, including radiofrequency ablation, sclerotherapy, nonthermal adhesive ablation, and open surgical stripping. Venous ablation is indicated in patients with symptoms and signs of venous disease that persist despite a trial of medical management, and documented reflux in the target superficial vein (ie, retrograde flow &gt;0.5 seconds). The patient's symptoms should directly relate to the incompetent veins being treated. (See  <a class="medical medical_review" href="/z/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Candidates for venous intervention'</a>.)</p><p>Based on the available studies, bilateral GSV ablations can be performed safely in a single setting using tumescent anesthesia (maximum dose 15 mg/kg). In a review of data from the Vascular Quality Initiative that compared staged EVLA in 939 patients with concomitant bilateral EVLA in 308 patients, overall complications were similar [<a href="#rid16">16</a>].</p><p>There may be some concern over the administered dose of local anesthetic that occurs when the bilateral saphenous vein EVLA is performed. Larger doses of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> are tolerated when a diluted solution of tumescent anesthesia is used compared with the subcutaneous injection (ie, maximal subcutaneous dose: 5 mg/kg for lidocaine without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>; 7 mg/kg with epinephrine) [<a href="#rid17">17,18</a>]. (See <a class="local">'Instill tumescent anesthetic'</a> below.)</p><p>Patients with lower extremity ulceration should be assessed to ensure the adequacy of the arterial circulation since patients with chronic venous disease complicated with ulceration can have coexistent peripheral artery disease. If the arterial circulation is inadequate for wound healing, the arterial disease should be addressed prior to treating the venous disease. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p>Endovenous ablation is associated with a very low risk of infection; thus, it is generally not necessary to wait for venous ulcers to heal prior to proceeding with EVLA. Faster ulcer healing occurs following endovenous management of associated superficial venous reflux. In a trial that randomly assigned 450 patients with active venous ulcers to compression therapy and early endovenous ablation or to compression therapy and delayed intervention (ie, until ulcer healing or six months after randomization), ulcer healing was faster, and time free from ulcers was longer in the early intervention group [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/15233.html" rel="external">"Comparison of methods for endovenous ablation for chronic venous disease", section on 'Ulcer healing'</a>.)</p><p>For patients with ulceration who are refractory to management or in whom ulceration recurs, evaluating for obstruction of the iliac vein should be considered. (See  <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">"Overview of iliocaval venous obstruction"</a>.)</p><p>Also, ablation of perforators can be considered, but treatment of perforating veins has not been demonstrated to improve ulcer healing [<a href="#rid20">20</a>]. </p><p class="headingAnchor" id="H3305633339"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>EVLA is contraindicated in patients with acute deep venous thrombosis and in pregnant patients due to the risk of developing a new deep vein thrombosis (DVT) [<a href="#rid21">21</a>]. We prefer to wait a minimum of six weeks after delivery in pregnant patients before performing EVLA. Circulating volume and uterine size will normalize by six weeks, diminishing the intensity of varicose vein symptoms. Post-partum, the incidence of thromboembolic events is significantly increased for the first six weeks but continues to be elevated for up to three months [<a href="#rid22">22</a>].</p><p>Patients with congenital venous abnormalities (eg, Klippel-Trenaunay syndrome, Parkes Weber syndrome) should generally not undergo ablation of major superficial veins. Selected patients may, however, benefit from localized management of symptomatic segments (sclerotherapy, stab phlebectomy). (See  <a class="medical medical_review" href="/z/d/html/121010.html" rel="external">"Overview of vascular intervention and surgery for vascular anomalies"</a> and  <a class="medical medical_review" href="/z/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Ambulatory phlebectomy'</a>.) </p><p>Relative contraindications to EVLA for a given vein segment that may result in failure to perform the procedure or subsequent failure of the procedure include:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic or recurrent phlebitis in the target vein, since formation of synechiae in the vein can prevent passage of the laser sheath. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe tortuosity in which passage of the device may not be possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Target veins that are not at least 1 cm deep to the skin dermis after tumescent anesthesia is administered. Ablation of veins closer to the skin may lead to skin burns. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Target great saphenous vein segments that are aneurysmal (&gt;2.5 cm in diameter) may have a greater risk of failure. </p><p></p><p class="headingAnchor" id="H60600649"><span class="h1">PATIENT COUNSELING</span><span class="headingEndMark"> — </span>The indications for the procedure, alternatives (eg, continued medical management, vein stripping), risks, and benefits (relief of symptoms attributable to the venous insufficiency) should be discussed with the patient. The patient is informed that:</p><p class="bulletIndent1"><span class="glyph">●</span>Unforeseen anatomic issues may result in failure (ie, the inability to perform an endovenous procedure), in which case the patient may need to be rescheduled for a repeat or alternative procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In spite of successful technical application of the endovenous device, nonclosure of the vein or late vein recanalization can occur and may be more common in larger diameter veins. In these cases, EVLA may be repeated or an alternative procedure performed. (See <a class="local">'Saphenous ablation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associated varicosities that have not been treated at the time of the EVLA should become less noticeable but may not completely disappear. Supplemental procedures may be needed to achieve the desired cosmetic result [<a href="#rid23">23,24</a>]. Whether simultaneous versus delayed sclerotherapy or phlebectomy is being performed should be understood prior to the procedure. (See <a class="local">'Perform supplemental procedures'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other risks of the procedure may include bleeding, infection, phlebitis, deep vein thrombosis, and cutaneous nerve injury leading to numbness or paresthesias. (See <a class="local">'Complications'</a> below.)</p><p></p><p>Alternatives to EVLA include no therapy, compression therapy, sclerotherapy, radiofrequency ablation, chemical ablation, mechanochemical ablation, nonthermal adhesive ablation, or surgical removal of refluxing superficial veins. (See  <a class="medical medical_review" href="/z/d/html/8206.html" rel="external">"Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins"</a> and  <a class="medical medical_review" href="/z/d/html/8203.html" rel="external">"Techniques for radiofrequency ablation for the treatment of lower extremity chronic venous disease"</a> and  <a class="medical medical_review" href="/z/d/html/121344.html" rel="external">"Approach to treating symptomatic superficial venous insufficiency", section on 'Surgical options'</a>.) </p><p class="headingAnchor" id="H715136692"><span class="h1">PATIENT PREPARATION</span><span class="headingEndMark"> — </span>The diagnostic evaluation is performed by taking a careful history, performing a physical exam, and obtaining noninvasive vascular laboratory studies. A venous duplex ultrasound of the affected lower extremity should evaluate the deep veins, great saphenous vein, accessory saphenous veins, if present, and small saphenous vein for patency as well as the presence of reflux. The clinical evaluation of lower extremity chronic venous insufficiency is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8198.html" rel="external">"Clinical manifestations of lower extremity chronic venous disease"</a> and  <a class="medical medical_review" href="/z/d/html/8196.html" rel="external">"Diagnostic evaluation of lower extremity chronic venous disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antithrombotic therapies</strong> — <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a>, antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs), direct oral anticoagulants (DOACs) are sometimes discontinued to limit postoperative bruising, but this is not necessary. </p><p></p><p class="bulletIndent1">For patients who are therapeutically anticoagulated, cessation of anticoagulation is <strong>not</strong> necessary prior to EVLA. Perioperative anticoagulation with low-molecular-weight heparin, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, or direct oral anticoagulants does not appear to affect the success of endovenous closure [<a href="#rid25">25-29</a>]. If cessation is selected, the timing of interruption depends on the agent. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Warfarin interruption'</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'DOAC interruptions (overview)'</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic antibiotics</strong> — Infection is rare following endovenous ablation procedures, and antibiotic prophylaxis is generally not needed prior to EVLA [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboprophylaxis</strong> — EVLA is a brief outpatient procedure with an overall low risk of deep vein thrombosis (DVT). DVT prophylaxis is needed only for high-risk patients. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vein mapping/marking</strong> — On the day of the procedure, the veins to be ablated may be marked (ie, marked with indelible ink), with duplex ultrasound to aid in the administration of tumescent anesthesia, but it is generally not necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scheduled follow-up</strong> — A prescheduled appointment should be made for follow-up duplex examination within seven days after EVLA. We prefer to obtain our duplex ultrasound two to four days following EVLA, since most endovenous heat-induced thrombus are believed to form within 72 hours; however, practice patterns reported in the literature vary [<a href="#rid31">31</a>] to assess for deep vein thrombosis. (See <a class="local">'Postoperative duplex ultrasound'</a> below and <a class="local">'Endovenous heat-induced thrombus'</a> below and <a class="local">'Deep vein thrombosis'</a> below.) </p><p></p><p class="headingAnchor" id="H2646153837"><span class="h1">MECHANISM OF ACTION AND LASER DEVICES</span><span class="headingEndMark"> — </span>Lasers emit a single, coherent wavelength of light  (<a class="graphic graphic_figure graphicRef69001" href="/z/d/graphic/69001.html" rel="external">figure 6</a>). Laser therapy of venous structures is based upon the concept of selective photothermolysis (ie, selective thermal confinement of light-induced damage) [<a href="#rid32">32</a>]. The wavelength of light is chosen based upon the chromophore (the part of a molecule responsible for its color) of the target tissue. Vein wall injury is mediated directly by absorption of photon energy by the vein wall (thermal radiation) and indirectly by thermal convection from steam bubbles and thermal conduction from heated blood [<a href="#rid32">32-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/2883.html" rel="external">"Basic principles of medical lasers"</a>.)</p><p>Commercially available devices for EVLA are manufactured by Angiodynamics (810 and 1470 nm diode lasers), Dornier MedTech (940 nm diode laser), Sciton (1319 nm Nd:YAG laser), CoolTouch (1320 nm Nd:YAG laser), and Biolitec (980 and 1470 nm diode lasers). The wavelength of laser may impact outcomes [<a href="#rid36">36-40</a>]. (See <a class="local">'Closure rates and recurrence'</a> below.)</p><p>In addition to wavelength, some have speculated that the type of fiber tip may affect the depth of tissue injury, postoperative pain, and bruising during EVLA [<a href="#rid41">41</a>]. As an example, the use of a bare laser fiber may lead to inhomogeneous vein wall destruction due to a tendency of the tip to become located eccentrically within the vein. Diminished postprocedure pain and bruising were found in patients treated with the 1470 nm laser catheters with a radial fiber compared with the bare-tip fiber [<a href="#rid42">42</a>]. A flared tip (Tulip Tip, Tobrix), designed to center the laser and promote more homogeneous heating, is commercially available in Europe but not in the United States. One trial using this device noted reduced postoperative ecchymosis and pain; however, the differences demonstrated were small and likely not clinically significant [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H715136764"><span class="h1">PROCEDURE</span><span class="headingEndMark"> — </span>EVLA can be performed in a clinic, office, or other outpatient surgery setting with oral <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> and local anesthesia with or without supplemental venous procedures [<a href="#rid44">44</a>]. If moderate sedation is used, a nurse should be dedicated to monitoring the patient's level of consciousness, heart rate, blood pressure, and oxygen saturation. Local tumescent anesthesia is required for the procedure to reduce the incidence of nerve injury and skin necrosis (if the vein is superficial), regardless of other forms of anesthesia such as general or regional anesthesia. Regional anesthesia (eg, femoral nerve bloc) may be a good option if the patient will undergo extensive concomitant phlebectomy [<a href="#rid45">45</a>]. </p><p>It is important that the patient is relaxed and well hydrated. An oral anxiolytic can be given approximately one hour prior to the procedure to help the patient relax. (See  <a class="medical medical_review" href="/z/d/html/16851.html" rel="external">"Acute procedural anxiety and specific phobia of clinical procedures in adults: Treatment overview", section on 'Benzodiazepines as first-line medication'</a>.)</p><p class="headingAnchor" id="H715136772"><span class="h2">Preparation</span></p><p class="headingAnchor" id="H715136780"><span class="h3">Equipment</span></p><p class="bulletIndent1"><span class="glyph">●</span>Duplex ultrasound machine – The procedure can be performed with a portable ultrasound machine (gray scale imaging); however, color duplex imaging with a vascular probe is ideal. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laser generator – The machine should be checked for proper functioning and calibrated, if necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tilt table – The ability to adjust the patient's position between Trendelenburg and reverse Trendelenburg is highly desirable. Alternatively, a venous tourniquet can be used to assist engorgement of the vein during access.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pump for tumescent anesthesia (eg, Klein pump) – The pump is used to infuse tumescent anesthesia but is not essential. If a Klein pump is not available, the tumescent anesthesia can be injected by hand.</p><p></p><p class="headingAnchor" id="H715136788"><span class="h3">Medications</span></p><p class="bulletIndent1"><span class="glyph">●</span>Local anesthetic for puncture site: 1% <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>. The addition of bicarbonate may help diminish the pain of injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumescent anesthetic (a mixture of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, bicarbonate, and <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> for subcutaneous injection). Dosing for tumescent anesthesia is discussed below. (See <a class="local">'Instill tumescent anesthetic'</a> below.)</p><p></p><p class="headingAnchor" id="H715136796"><span class="h3">Materials</span></p><p class="bulletIndent1"><span class="glyph">●</span>Preparation materials: skin prep, gown, mask, and sterile gloves</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Draping materials: sterile drape, bag, or towel for foot</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubing for tumescent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>10 mL syringe with 16- to 20-gauge needle to draw up anesthetic, 25- to 30-gauge needle to inject</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Micropuncture sheath kit: micropuncture wire (0.035"), 4F device dilator/sheath</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echogenic 21-gauge micropuncture needle</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional guidewires: glidewire (0.018") </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wound dressing: gauze and elastic wrap or thigh-high elastic stocking with gauze pads, or adhesive strips or bandages</p><p></p><p class="headingAnchor" id="H715136804"><span class="h2">General technique</span><span class="headingEndMark"> — </span>EVLA is performed according to the manufacturer's recommendations. The general technique is described below.</p><p>The patient is positioned supine for treatment of the great saphenous vein (GSV) or accessory saphenous veins (ASVs). The prone position is preferred for treatment of the small saphenous vein (SSV), but it can be successfully treated in the supine position. The leg should be prepped to include the saphenofemoral junction (for treatment of the GSV) or the saphenopopliteal junction (for treatment of the SSV) since these areas must be imaged with ultrasound.</p><p class="headingAnchor" id="H715136820"><span class="h3">Place the device sheath</span><span class="headingEndMark"> — </span>The patient is placed in reverse Trendelenburg position to engorge the target vein and facilitate venous access. Using ultrasound guidance, a micropuncture cannula is introduced into the vein near the mid-calf for GSV ablation or near the ankle for SSV ablation and a long guidewire advanced toward the saphenofemoral junction (or saphenopopliteal junction).</p><p>On occasion, the vein may develop spasm during venipuncture. Carefully selecting an accessible portion of the vein and successfully obtaining access upon the first attempt greatly reduces the risk of vasospasm. Placement of a venous tourniquet just cephalad to the vein or the application of 2% <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> paste over the vein may break the spasm and prevent the need for a second venipuncture. Alternatively, a cutdown to access the vein can be performed.</p><p>Difficulty advancing the wire or the sheath into the vein more cephalad may be encountered in the presence of a tortuous vein, venous aneurysms, or vein segments that are sclerotic or occluded. Severely tortuous vein segments cannot be treated, though this should be recognized in advance on preoperative duplex ultrasound. Mildly tortuous venous segments, sclerotic segments, and venous aneurysms can usually be crossed with straightening the leg, manual manipulation of the overlying skin, or by using a hydrophilic wire (eg, glidewire). Segmental occlusions can be managed with two treatments administered through two separate sheaths placed cephalad and caudal to the occlusion. </p><p class="headingAnchor" id="H715136828"><span class="h3">Position the catheter</span><span class="headingEndMark"> — </span>A 4 French laser sheath is advanced over the wire and positioned in the vein. Correct catheter position is critical to reduce the risk of deep vein thrombosis. The tip of the laser should be placed at least 2 cm below the saphenofemoral (or saphenopopliteal) junction and the position confirmed with ultrasound. Ideally, the catheter tip should be just caudal to at least one tributary vein to ensure continued flow in the more cephalad vein. Be aware of arteries in close proximity to the vein to minimize the possibility of creating an arteriovenous fistula [<a href="#rid46">46</a>]. Examples include a deep external pudendal artery coursing posterior to the GSV near the saphenofemoral junction and sural artery branches in proximity to the SSV or perforators.</p><p>Patients with variant SSV anatomy with no tributaries to the SSV in the popliteal region may be at a higher risk for deep venous thrombosis [<a href="#rid9">9</a>]. (See <a class="local">'Venous anatomy'</a> above and <a class="local">'Small saphenous vein'</a> below.)</p><p>Once the sheath is in place, the patient should be placed in the Trendelenburg position. This serves to empty the vein and allow better contact of the laser catheter to the wall of the vein, which may help reduce postprocedure pain. </p><p>The laser sheath is backed out to expose the tip of the laser catheter. The position of the tip of the catheter should be rechecked with ultrasound and correct placement confirmed. This is a critical portion of the procedure. Sometimes air bubbles in the gel or hair around the groin can reduce visibility. Also, imaging the catheter in patients with obesity can be a challenge. If technical issues obscure the catheter, and its position cannot be positively ascertained, the procedure should be aborted and an alternative procedure performed (eg, vein stripping, sclerotherapy). </p><p class="headingAnchor" id="H715136836"><span class="h3">Instill tumescent anesthetic</span><span class="headingEndMark"> — </span>With ultrasound imaging, an echogenic micropuncture needle is used to inject tumescent anesthesia into the tissue surrounding the vein. Tumescent anesthesia has several important functions, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Providing anesthesia during EVLA</p><p class="bulletIndent1"><span class="glyph">●</span>Facilitating contact of the vein wall with the laser tip</p><p class="bulletIndent1"><span class="glyph">●</span>Deepening the vein relative to the skin to protect the skin from damage during laser treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Acting as a heat sink to protect surrounding tissues, especially sensory nerves, from thermal damage during laser treatment</p><p></p><p>The accepted maximum dose of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> in tumescent anesthesia is between 15 and 55 mg/kg [<a href="#rid34">34,35</a>]. Most available reports evaluating lidocaine toxicity using tumescent anesthesia are in patients undergoing liposuction for which a portion of the lidocaine is theoretically removed during the liposuction. One report used 14 volunteers to perform 41 tumescent anesthetics with varying doses of lidocaine ranging from 19.2 mg/kg to 52 mg/kg. The authors estimated the maximum safe dosage of lidocaine in tumescent anesthesia was 28 mg/kg without liposuction and 45 mg/kg with liposuction [<a href="#rid47">47</a>]. In an observational study of patients undergoing EVLA, 5 of 11 patients experienced symptoms of toxicity when administered 35 mg/kg of tumescent anesthesia in the perivenous space, but none of the eight patients who were administered 15 mg/kg experienced symptoms of toxicity [<a href="#rid17">17</a>]. With undiluted lidocaine with epinephrine (ie, 7 mg/kg max), only 500 mL of tumescent anesthesia could be used, which is roughly the amount required to perform EVLA of a single GSV. </p><p>After completion of the tumescent anesthesia, it is important to confirm with ultrasound that a halo of tumescent anesthetic surrounds the catheter, especially in the region of the saphenofemoral junction, and to ensure that the catheter and vein are at least 1 cm deep to the skin. </p><p class="headingAnchor" id="H715136844"><span class="h3">Ablate the vein</span><span class="headingEndMark"> — </span>After adequate tumescent anesthesia has been delivered, the vein is ready for treatment. The catheter is slowly pulled back at an initial rate of 1 mm every second for the first 10 cm of treatment length. Thereafter, the catheter can be pulled back 2 to 3 mm every second. A slow, steady pullback provides even heating of the entire vein segment and minimizes the chance of vein perforation.</p><p class="headingAnchor" id="H715136852"><span class="h3">Perform completion ultrasound</span><span class="headingEndMark"> — </span>Following completion of the procedure, ultrasound examination of the common femoral vein (or popliteal vein for treatment of the SSV) is performed to confirm patency and exclude thrombus. Closure of the treated vein is confirmed. The vein should appear thickened (ie, hyperechoic doughnut) with thrombus in its lumen with no identifiable venous flow. The vein near the saphenofemoral junction should be compressible and hypoechoic and without the presence of any intraluminal debris, which would appear hyperechoic. If the vein is thickened but has a narrowed lumen with persistent color Doppler flow, we observe these patients. On follow-up, the saphenous vein typically scars down and the vein occludes typically over the next month.</p><p class="headingAnchor" id="H715136860"><span class="h3">Perform supplemental procedures</span><span class="headingEndMark"> — </span>Following successful closure of the target veins, the extremity is evaluated for any significant residual varicose veins, which can be managed with phlebectomy or sclerotherapy depending upon their size and operator preference. The supplemental procedures can be performed immediately following EVLA, or as deferred treatment. When we identify large (&gt;8 mm) varicose tributaries, we selectively perform phlebectomy or sclerotherapy at the time of the EVLA to prevent superficial thrombophlebitis, especially if the varicosity is still bulging at the completion of the procedure. The main advantage of supplemental procedures concomitant with EVLA is a reduction in the overall treatment time. </p><p>The majority of smaller varicose tributaries (&lt;8 mm) will significantly reduce in size to a new baseline within six weeks due to the reduced venous pressure. The advantage of waiting four to six weeks following EVLA is that the residual veins will be smaller and more amenable to injection sclerotherapy, rather than phlebectomy. In addition, up to 40 percent of patients will require no further treatment [<a href="#rid48">48-52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One trial randomly assigned 50 patients to EVLA with concomitant phlebectomy or EVLA with sequential phlebectomy [<a href="#rid49">49</a>]. The concomitant treatment group required longer operative times, fewer subsequent procedures (1 of 25 versus 16 of 25), and a trend toward longer time to return to work (10 versus 3 days). The concomitant treatment group also had a lower health-related quality of life (HRQOL) at six weeks and three months; however, no differences in HRQOL were seen at one year and remained equal at five years [<a href="#rid50">50</a>]. It is important to note that in the sequential treatment group, a supplemental procedure was not needed in one-third of the patients. Similarly, a retrospective study of 80 patients treated with EVLA alone found that supplemental treatment was needed in only 42 percent of patients [<a href="#rid51">51</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A comprehensive review of over 300 limbs treated with EVLA and sequential phlebectomy identified anatomic and clinical factors associated with lack of regression of superficial varicosities following EVLA [<a href="#rid52">52</a>]. CEAP (Clinical, Etiologic, Anatomic, Pathophysiologic) classification did not affect the need for secondary procedures. An increased likelihood of requiring secondary procedures was found for enlarged (&gt;6 mm) GSV in the distal thigh, patients with clusters of large (&gt;6 mm) diameter varicosities, and patients in whom the cosmetic appearance was very important. These patients might benefit from a combined EVLA and phlebectomy performed as a single-stage procedure. </p><p></p><p class="headingAnchor" id="H3185539653"><span class="h3">Apply compression</span><span class="headingEndMark"> — </span>Following the completion of the procedure, a light bandage is placed over the EVLA puncture site and any phlebectomy sites, and compression is applied. The type of compression prescribed and duration of compression vary widely [<a href="#rid53">53,54</a>]. Generally, either previously prescribed thigh high compression stocking, or wraps, are placed.</p><p class="headingAnchor" id="H183020874"><span class="h2">Specific anatomic sites</span><span class="headingEndMark"> — </span>The technical aspects of the EVLA procedure vary with the anatomic site. Venous anatomy is described above. (See <a class="local">'Venous anatomy'</a> above and <a class="local">'Anatomy'</a> above.) </p><p class="headingAnchor" id="H715136876"><span class="h3">Great saphenous vein</span><span class="headingEndMark"> — </span>Treating the saphenous vein in the lower calf is rarely necessary because most patients obtain adequate relief of their venous symptoms without extending the ablation below the mid-calf. Doing so may increase the risk of saphenous nerve injury. (See <a class="local">'Nerve injury'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>One trial randomly assigned 65 patients with above- and below-knee GSV reflux into three groups: above-knee GSV EVLA, mid-calf to groin (extended) GSV EVLA, or above-knee EVLA plus below-knee GSV foam sclerotherapy [<a href="#rid55">55</a>]. All patients experienced significant improvements in symptoms; the extended EVLA group had the highest patient satisfaction and the lowest requirement for subsequent sclerotherapy, and the below-knee foam sclerotherapy group was a close second. The need for additional sclerotherapy was 61 percent in the above-knee EVLA group versus 17 and 36 percent in the extended GSV EVLA and above-knee plus below-knee GSV foam group, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The same group of investigators evaluated 69 below-knee GSV segments with duplex ultrasound six weeks following above-knee GSV EVLA and found 59 percent had no or minimal reflux [<a href="#rid56">56</a>]. All patients experienced significant improvement in symptoms, but patients with persistent reflux in the below-knee GSV more often required sclerotherapy for residual symptomatic varicose veins. </p><p></p><p>Studies have evaluated alterations in technique to improve closure rates in large diameter GSV. One study reviewing the evolution of their management reported on 88 patients treated for large-diameter GSV (mean 22 mm; range 15 to 34 mm) using a 1560 nm wavelength laser [<a href="#rid36">36</a>]. The first third underwent open ligation of the saphenofemoral junction combined with EVLA and had no failures. The second third underwent EVLA using 90 J/cm for the more cephalad vein; among these, type 2 failure (recanalization) occurred in four patients (13.2 percent) with body mass index (BMI) &gt;40. A second EVLA in these patients was ultimately successful. The last third underwent a personalized EVLA procedure: for patients with vein diameters 15 to 20 mm, the energy used was 100 J/cm for the more cephalad vein; for vein diameters 20 to 30 mm, the energy used was 150 J/cm for the more cephalad vein. The third group had no failures and included five patients with BMI &gt;40.</p><p class="headingAnchor" id="H3198643895"><span class="h3">Accessory saphenous vein</span><span class="headingEndMark"> — </span>Clinical failure following EVLA of the GSV can be due to large refluxing accessory saphenous tributaries  (<a class="graphic graphic_figure graphicRef55019 graphicRef52340" href="/z/d/graphic/55019.html" rel="external">figure 1A-B</a>). As a result, we prefer to treat ASVs that demonstrate significant reflux at the same time as GSV ablation. The second sheath needs to be placed in the ASV prior to instillation of tumescent anesthesia. We treat the GSV first since it is usually the larger vein.</p><p class="headingAnchor" id="H715136884"><span class="h3">Small saphenous vein</span><span class="headingEndMark"> — </span>Anatomic variation in the saphenopopliteal junction is common [<a href="#rid11">11</a>]. In approximately 30 percent of patients, the SSV does not communicate with the popliteal vein; rather, it drains cephalad, continuing as the intersaphenous vein (vein of Giacomini). In some individuals, the SSV drains into the popliteal vein directly with no significant tributaries. These patients have a higher risk of developing deep venous thrombosis with SSV endovenous ablation [<a href="#rid9">9</a>]. (See <a class="local">'Deep vein thrombosis'</a> below.) </p><p>Compared with puncture at the ankle level, puncture of the SSV at the midcalf level in one trial of 60 patients resulted in fewer postoperative paresthesias without affecting the success of closure at six months follow-up [<a href="#rid57">57</a>]. (See <a class="local">'Nerve injury'</a> below.)</p><p class="headingAnchor" id="H715136892"><span class="h3">Perforator veins</span><span class="headingEndMark"> — </span>Although there are special catheters designed to treat incompetent perforating veins (eg, Venacure), there are no studies showing that treatment of incompetent perforating veins leads to faster ulcer healing or a decreased incidence of ulcer recurrence. Studies that have evaluated patients undergoing treatment for incompetent perforating veins almost universally include patients with combined treatment of an incompetent GSV, making analysis of the clinical utility of adding the treatment of perforating veins difficult to determine. </p><p class="headingAnchor" id="H715136900"><span class="h1">FOLLOW-UP CARE</span></p><p class="headingAnchor" id="H715136908"><span class="h2">Pain management</span><span class="headingEndMark"> — </span>Pain can usually be controlled with over-the-counter pain medications (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>). Extensive concurrent vein excision (phlebectomy) may require stronger analgesics (eg, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>). In one study, 85 percent of patients complained of no or minimal pain [<a href="#rid58">58</a>]. Moderate to severe pain is experienced in 4 to 9 percent of patients [<a href="#rid59">59,60</a>]. Pain gradually resolves with time and is improved by wearing compression stockings. (See <a class="local">'Duration of compression therapy'</a> below.)</p><p>Nonsteroidal anti-inflammatory drugs can be added for patients who develop a significant phlebitic reaction. An ice pack can also be applied to the affected areas for comfort. (See <a class="local">'Superficial thrombophlebitis'</a> below.) </p><p class="headingAnchor" id="H1229227692"><span class="h2">Patient instructions</span><span class="headingEndMark"> — </span>In the absence of concerning symptoms, the patient should be seen in the office within six weeks of the procedure to reevaluate the clinical symptoms/signs of venous disease and determine the need and timing for any possible supplemental procedures. (See <a class="local">'Perform supplemental procedures'</a> above.) </p><p>Concerning clinical symptoms that should prompt the patient to call their physician include:</p><p class="bulletIndent1"><span class="glyph">●</span>Swelling or excessive pain that is not relieved with the prescribed pain medications may be a symptom of deep vein thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Numbness, tingling, coolness, or discoloration of the toes of the treated extremity. The compression bandages/stockings may be too tight and need to be removed.</p><p></p><p>Our routine instructions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ambulate normally and take short (20 minute) leisure walks three times daily. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid prolonged standing and sitting; when seated, elevate the treated extremity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Refrain from strenuous cardiovascular activities (eg, heavy aerobic exercise) for one to two weeks; thereafter, resume normal activities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resume normal job duties within three to four days; however, jobs requiring prolonged standing and/or heavy lifting may require additional time off.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintain the postoperative dressing and elastic bandages/stockings until the postoperative duplex examination, which should occur within two to three days following the procedure. (See <a class="local">'Postoperative duplex ultrasound'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reinforce any areas of bleeding that occur through the dressing, but patients should call their physician if excessive bleeding occurs. This is more commonly associated with vein excisions performed at the same time as the endovenous ablation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wear thigh-high graded compression stockings day and night for one to two weeks following the procedure. However, the optimal compression regimen following EVLA has not been well studied, and differing types and duration have been used successfully [<a href="#rid53">53</a>]. (See <a class="local">'Duration of compression therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do not be alarmed if there is a pulling sensation or tightness over the treated vein. This is due to the scarring of the vein, which adheres to the surrounding tissues. Gentle stretching exercises in the region of the treated vein may be helpful. For great saphenous ablation, stretching the inner thigh region is accomplished by sitting on the floor with the feet pressed together and leaning forward. For the small saphenous vein, stretching the vein is accomplished by leaning forward against a wall with the affected leg placed behind the hips with the foot flat on the floor.</p><p></p><p class="headingAnchor" id="H304754192"><span class="h2">Postoperative duplex ultrasound</span><span class="headingEndMark"> — </span>All patients should undergo duplex ultrasound within seven days following the procedure to rule out deep vein thrombosis [<a href="#rid59">59,61</a>]. The main purpose of the postoperative duplex study is to carefully evaluate the extent of the ablated vein for thrombus and to determine whether any thrombus extends into the deep veins. (See <a class="local">'Endovenous heat-induced thrombus'</a> below and <a class="local">'Deep vein thrombosis'</a> below.)</p><p>When patients treated with EVLA for venous ulceration develop recurrence, we reevaluate them with duplex ultrasound, looking for residual/recurrent superficial venous reflux. In the absence of significant superficial venous reflux, we consider obtaining a computed tomographic venogram to evaluate for central vein obstruction in the iliac veins. (See  <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">"Overview of iliocaval venous obstruction"</a>.)</p><p class="headingAnchor" id="H4137582262"><span class="h2">Duration of compression therapy</span><span class="headingEndMark"> — </span>The duration of compression following EVLA varies widely in the literature [<a href="#rid57">57</a>]. We suggest one week of compression following EVLA. We recommend a second week of wearing compression if it improves postprocedure pain. </p><p>Several trials have addressed this issue and have randomized patients to wearing compression stockings for one to two weeks compared with zero to two days following EVLA [<a href="#rid58">58-60</a>]. Most of these trials have found diminished edema, pain, and use of pain medication for the first one to two weeks in patients who wore compression stockings longer. There was no difference in time to return to work, vein closure rates, or deep venous thrombosis. One trial found no difference in pain or bruising in patients who wore compression stockings following the procedure compared with patients who did not wear compression stockings. This trial evaluated 85 limbs, 91 percent of which underwent radiofrequency ablation; only 9 percent underwent EVLA with an 890 nm wavelength laser [<a href="#rid58">58</a>]. </p><p class="headingAnchor" id="H164906636"><span class="h2">Return to normal activities</span><span class="headingEndMark"> — </span>We usually suggest that patients wait three to five days before going back to work. Patients who stand or walk more as part of their work typically need to take off more time.</p><p>The time to return to normal activities or return to work has varied among the available clinical trials. One trial of 99 patients reported a decreased time to return to normal activity (2 versus 7 days) and return to work (4 versus 17 days) for EVLA compared with GSV ligation and stripping [<a href="#rid61">61</a>].</p><p>On the other hand, two trials involving 200 and 121 patients found no significant differences in return to normal activity or work (average, seven days) [<a href="#rid62">62,63</a>]. Yet another trial found a longer time until return to work for EVLA compared with GSV ligation and stripping (20 versus 14 days) [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H361481576"><span class="h1">CLOSURE RATES AND RECURRENCE</span></p><p class="headingAnchor" id="H889007126"><span class="h2">Saphenous ablation</span><span class="headingEndMark"> — </span>Initial technical and short-term success for treatment of the great saphenous vein (GSV) ranges from 90 to 100 percent [<a href="#rid1">1,4,7,60,62-66</a>]. Most reports demonstrate 97 to 98 percent short-term success rates. In large retrospective studies, varicose vein recurrence was reported in 7 to 14 percent of patients long-term (two to seven years) following EVLA [<a href="#rid5">5,67-72</a>]. Varicose vein recurrence is reported with long-term follow-up at rates that are similar to radiofrequency ablation [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H3404403215"><span class="h3">Large veins</span><span class="headingEndMark"> — </span>Whether vein diameter is a significant factor in determining closure rates is debated [<a href="#rid60">60,62,63</a>]. In the author's experience, failures are rare but are more common with very large vein diameters, typically greater than 2 cm in patients with high BMI. A BMI &gt;40 has also been reported to affect closure rates. Some have suggested that veins with a diameter &gt;8 to 10 mm are associated with a higher risk of nonocclusion [<a href="#rid60">60,62,63</a>]. As an example, in a review of 500 patients treated with EVLA, 98 percent of GSVs were successfully closed on the initial postprocedure duplex ultrasound. After four years, the closure rate had decreased to 97 percent. All failures occurred in patients with a saphenofemoral junction &gt;11 mm or a GSV diameter &gt;8 mm [<a href="#rid60">60</a>]. In another study, initial success for EVLA of the GSV was 95 percent [<a href="#rid62">62</a>]. In the successfully treated veins, the average maximum vein diameter was 11 mm, whereas for the failures, the mean maximum vein diameter was 21 mm. In a review that included 287 patients treated with either radiofrequency ablation or EVLA, higher rates of recanalization were more common in patients with GSV diameter &gt;10 mm [<a href="#rid63">63</a>].</p><p>Other reports demonstrate equal effectiveness for treating very large GSVs compared with smaller veins. One study found no significant differences in the failure rates of EVLA in 732 patients with large diameter veins &gt;10 mm compared with smaller diameter veins (4.5 versus 3.4 percent) [<a href="#rid73">73</a>]. Large veins constituted 12 percent of the total veins treated, and 1 percent of the veins had a diameter &gt;20 mm. The vein obliteration rate in the largest veins (20 to 24 mm) was 100 percent. In another study of 38 consecutive ablations, 20 GSVs measured &gt;1 cm in diameter, and four measured &gt;2 cm in diameter [<a href="#rid74">74</a>]. Successful ablation was achieved in 100 percent of veins, independent of vein diameter. A third study evaluated 49 EVLA procedures on large GSVs (mean diameter 17 mm; range 15 to 26 mm diameter) and noted a failure rate of 2.1 percent, which was similar to the rate for EVLA of smaller GSVs [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H2592114796"><span class="h2">Accessory saphenous ablation</span><span class="headingEndMark"> — </span>Short-term results of EVLA of the accessory saphenous vein (ASV) and small saphenous vein (SSV) have shown closure rates similar to GSV EVLA with minimal complications [<a href="#rid67">67,76-80</a>]. The primary success rates are 87 to 98 percent for the anterior ASV and 91 to 93 percent for the SSV [<a href="#rid67">67,73,81,82</a>]. However, in one single-center retrospective review of 732 EVLAs, the rate of failure to close was significantly higher for the ASV and SSV compared with the failure rate for the GSV (8.8 percent and 13.2 percent versus 1.6 percent, respectively) [<a href="#rid73">73</a>]. In a trial that randomly assigned 106 patients with unilateral, primary SSV reflux to EVLA or surgery, reflux was eliminated in significantly more patients treated with EVLA compared with surgery (96 versus 72 percent) [<a href="#rid83">83</a>]. The high failure rate in the surgery group was primarily due to an inability to strip the SSV because of tortuosity or vein breakage. Despite the increased incidence of persistent axial reflux in the SSV, the symptomatic improvement was the same in both groups and remained the same after two years. </p><p class="headingAnchor" id="H58911323"><span class="h2">Perforator ablation</span><span class="headingEndMark"> — </span>Studies are not available looking at long-term success or clinical outcomes (eg, ulcer healing) of EVLA for perforators. Feasibility studies have shown that EVLA is technically possible and appears safe [<a href="#rid84">84-86</a>]. In a trial that randomly assigned 69 patients to EVLA of incompetent thigh perforators draining into the GSV or EVLA of the GSV, technical success rates for perforator ablation were significantly lower compared with great saphenous ablation (77 versus 100 percent) [<a href="#rid86">86</a>]. Both groups experienced similar clinical success, and both groups had a single recanalization of the GSV between one week and one month.</p><p class="headingAnchor" id="H1409818108"><span class="h1">LOCAL ADVERSE REACTIONS</span><span class="headingEndMark"> — </span>EVLA is generally well tolerated. EVLA is associated with variable levels of pain, and randomized trials have found more pain [<a href="#rid87">87,88</a>], less pain [<a href="#rid4">4,89</a>], or no difference in pain [<a href="#rid6">6,58,90</a>] in patients undergoing great saphenous EVLA compared with other ablation therapies. Similar results have been noted for small saphenous vein EVLA [<a href="#rid91">91</a>]. </p><p class="headingAnchor" id="H2884046974"><span class="h2">Bruising/hematoma</span><span class="headingEndMark"> — </span>Approximately 60 percent of patients treated with EVLA have ecchymosis to some extent [<a href="#rid4">4</a>]. The median time to resolution is approximately two weeks. Lower and higher incidences of bruising have also been reported [<a href="#rid4">4,6,58</a>] compared with vein stripping. More severe bruising is probably related to perforation of the treated vein, which may have been due to contact of laser tip with the vein wall.</p><p>Hematoma occurs in 1 to 5 percent of patients undergoing EVLA of the great saphenous vein (GSV) [<a href="#rid6">6,44,59</a>]. One trial that randomly assigned 200 patients to EVLA or GSV ligation and stripping found significantly more hematomas in patients who underwent GSV ligation and stripping (12 versus 5) [<a href="#rid6">6</a>]. Another trial found that the size of hematomas that occurred was significantly smaller at one week for EVLA compared with surgical stripping [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H3059353003"><span class="h2">Skin burns</span><span class="headingEndMark"> — </span>Skin burns are a preventable complication and should be a rare occurrence following EVLA. The infusion of adequate amounts of tumescent anesthesia should be performed to ensure that the treated vein is more than 1 cm below the skin surface. Investigators performing EVLA without tumescent anesthesia have reported an incidence of skin burns of approximately 5 percent [<a href="#rid38">38</a>]. (See <a class="local">'Instill tumescent anesthetic'</a> above.) </p><p class="headingAnchor" id="H897703773"><span class="h2">Superficial thrombophlebitis</span><span class="headingEndMark"> — </span>A mild superficial thrombophlebitis is anticipated along the course of the ablated vein [<a href="#rid92">92</a>]. In addition, varicose veins that are in direct communication with the treated vein may thrombose or collapse and scar down. The reported incidence of symptomatic phlebitis following EVLA ranges from 0 to 5.2 percent and does not appear to be related to whether or not concomitant phlebectomy was performed [<a href="#rid4">4,38,58-60,93</a>].</p><p>Superficial thrombophlebitis is managed conservatively. Thrombosed veins that are painful and tender can be treated with cold compresses and nonsteroidal anti-inflammatory drugs (eg, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>). More significant signs or symptoms of pain or edema warrant ultrasound examination to evaluate for thrombus extending from the saphenous vein into the common femoral vein. </p><p class="headingAnchor" id="H271512919"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Although EVLA is generally well tolerated, a variety of complications can occur. The most important are thrombus extension (ie, endovenous heat-induced thrombus [EHIT]), deep vein thrombosis (DVT), and nerve injury. Local adverse reactions, such as skin bruising/hematoma, skin burns, and superficial thrombophlebitis, are discussed above. (See <a class="local">'Local adverse reactions'</a> above.)</p><p>A review from the National Surgical Quality Improvement Program (NSQIP) included 1786 patients undergoing EVLA [<a href="#rid94">94</a>]. Surgical site infection was less common for EVLA compared with vein stripping (0.5 versus 1.4 percent); however, deep venous thrombosis occurred more frequently with EVLA (1.6 versus 0.8 percent). </p><p><strong>Anatomic failure</strong> — Following saphenous ablation, duplex ultrasound can show procedural failure, but some of these patients have clinical improvement that is maintained long-term. Anatomic failure is a useful term to distinguish these patients from those with clinical failure (ie, recurrent clinical symptoms and/or varicose veins) [<a href="#rid95">95</a>]  (<a class="graphic graphic_table graphicRef121325" href="/z/d/graphic/121325.html" rel="external">table 1</a>). (See <a class="local">'Closure rates and recurrence'</a> above.)</p><p class="headingAnchor" id="H942810989"><span class="h2">Endovenous heat-induced thrombus</span><span class="headingEndMark"> — </span>Thrombus propagating from the ablated superficial vein into the deep vein cephalad to the level of the ablation can lead to DVT, although DVT is uncommon [<a href="#rid59">59</a>]. This process has been termed EHIT.</p><p class="headingAnchor" id="H896478802"><span class="h3">EHIT classification</span><span class="headingEndMark"> — </span>Several classification systems have been proposed to provide an accurate description of the level of EHIT following great saphenous venous ablation for the purpose of guiding clinical therapy and further research [<a href="#rid31">31,96,97</a>]. Much of the literature refers to the Kabnick classification  (<a class="graphic graphic_figure graphicRef111960" href="/z/d/graphic/111960.html" rel="external">figure 8B</a>). The latest classification scheme from the American Venous Forum/Society for Vascular Surgery is a minor modification of the Kabnick classification subdividing EHIT 1 depending on the degree of propagation of the thrombus  (<a class="graphic graphic_figure graphicRef130659" href="/z/d/graphic/130659.html" rel="external">figure 7</a> and <a class="graphic graphic_figure graphicRef112355 graphicRef111960" href="/z/d/graphic/112355.html" rel="external">figure 8A-B</a>) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H41649085"><span class="h3">Risk factors for EHIT</span><span class="headingEndMark"> — </span>Many factors have been purported to increase the risk for EHIT [<a href="#rid31">31</a>]. Among those suggested, larger vein diameter, less than 2.5 cm distance of the tip of the catheter from the saphenofemoral junction, history of thrombophilia, and possibly prior deep vein thrombosis or superficial vein thrombosis appear to be the most relevant following EVLA [<a href="#rid59">59,93,96,98-105</a>].</p><p>Larger vein diameter may be a risk factor for great saphenous vein (GSV) EHIT. In a retrospective review of 312 perioperative vein mappings, patients with valvular incompetence at the saphenofemoral junction or a large proximal GSV diameter had a significantly increased risk of developing EHIT [<a href="#rid106">106</a>]. Patients who developed EHIT had a mean great saphenous diameter of 13.1 mm, and 11 percent had saphenofemoral junction incompetence. By comparison, those who did not develop EHIT had a mean diameter of 8.4, and only 0.44 percent had saphenofemoral junction incompetence.</p><p>A review of over 4000 EVLA treatments supported the notion that increasing the distance of the laser tip from the saphenofemoral junction reduces the risk of EHIT [<a href="#rid107">107</a>]. In this study, there was a trend toward a decreased incidence of EHIT when the tip of the catheter was ≥2.5 cm compared with 2 cm from the junction (2.3 versus 1.3 percent).</p><p>However, a separate review that included 519 great or anterior saphenous vein EVLA procedures did not identify vein diameter, short distance of the catheter tip to saphenofemoral junction, type of endovenous ablation (radiofrequency versus EVLA), concomitant treatments (sclerotherapy, phlebectomy), or perioperative anticoagulation as risk factors for EHIT [<a href="#rid98">98</a>]. Rather, on multivariate analysis, male sex and Caprini thrombosis risk score (<a class="calc calc_professional" href="/z/d/html/131707.html" rel="external">calculator 2</a>) were the only significant risk factors.</p><p class="headingAnchor" id="H3450328254"><span class="h3">EHIT treatment and follow-up</span><span class="headingEndMark"> — </span>Consensus guidelines from the American Venous Forum/Society for Vascular Surgery recommended the following treatments based on the unified EHIT classification scheme  (<a class="graphic graphic_figure graphicRef130659" href="/z/d/graphic/130659.html" rel="external">figure 7</a>) [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Class I: No treatment, no routine follow-up imaging needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class II: Weekly surveillance ultrasound until the thrombus has retracted from the deep vein, consider treatment with antiplatelet agents or anticoagulation for high-risk patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class III: Therapeutic anticoagulation and weekly surveillance until the thrombus has retracted from the deep vein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Class IV: Treatment is individualized, but in general, therapeutic anticoagulation per guidelines for treatment of deep venous thrombosis. </p><p></p><p>Superficial venous thrombosis due to EHIT is thought to be more benign than spontaneous thrombus in this location. Nevertheless, we typically treat Class II EHIT with therapeutic anticoagulation and have noted that in most cases, the thrombus retracts from the deep vein within one to two weeks. (See  <a class="medical medical_review" href="/z/d/html/8199.html" rel="external">"Superficial vein thrombosis and phlebitis of the lower extremity veins", section on 'Treatment of SVT'</a>.)</p><p>In a review of 500 EVLA procedures, EHIT occurred in 4.9 percent at the saphenofemoral junction and in 6.3 percent at the saphenopopliteal junction [<a href="#rid93">93</a>]. Using the Lawrence classification system  (<a class="graphic graphic_figure graphicRef112355" href="/z/d/graphic/112355.html" rel="external">figure 8A</a>), 25 patients developed EHIT at the saphenofemoral junction, three were classified as level III and seven as level IV, all 10 of which were treated with observation. All patients with level III and three of the patients with level IV EHIT resolved at one week; the other four patients with level IV resolved between two to seven weeks.</p><p class="headingAnchor" id="H2743507843"><span class="h4">Deep vein thrombosis</span><span class="headingEndMark"> — </span>Thromboembolic complications following EVLA are uncommon. The incidence of DVT varies in the literature depending upon whether routine duplex ultrasound is performed within two to three days following EVLA and how well the saphenofemoral junction is examined. An experienced technician should perform the examination [<a href="#rid99">99,108</a>] (see <a class="local">'Postoperative duplex ultrasound'</a> above). </p><p>Some large series of EVLA with duplex ultrasound follow-up have noted 0 percent incidence of DVT [<a href="#rid4">4,58,60,108</a>], while others report an incidence of 0.9 to 2.3 percent [<a href="#rid59">59,84,93,96,99</a>]. A meta-analysis that included over 16,000 patients reported that the incidence of EHIT level V was 0.3 percent, and pulmonary embolism (PE) occurred in 0.1 percent [<a href="#rid109">109</a>]; the author's experience is consistent with these results. Stroke in a patient with DVT and a patent foramen ovale has also been reported following EVLA [<a href="#rid110">110</a>]. Some of the variation in the incidence of DVT may be related to how well the saphenofemoral junction is examined with duplex ultrasound following EVLA. An experienced technician should perform the examination.</p><p>DVT due to endovenous therapies usually resolves quicker compared with spontaneous DVT [<a href="#rid59">59,96</a>]. In the review of 500 EVLA procedures described above [<a href="#rid93">93</a>], of the 12 patients with level V EHIT, six were not treated with anticoagulation and all resolved in one week. The other six patients with level V were treated, and the thrombus retracted between two and six weeks. All three patients with level VI EHIT were treated with anticoagulation, with the DVT resolving within six weeks, at which point anticoagulation was discontinued. None of the patients developed a pulmonary embolism.</p><p>Specifically for EHIT, some investigators have used novel oral anticoagulants to avoid subjecting patients to low-molecular-weight-heparin injections [<a href="#rid111">111</a>]. One study included 21 patients with EHIT who were treated using <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. Nine patients had level 2 to 3 EHIT and were treated with 20 mg daily; 12 patients had level 4 to 5 EHIT and were treated with 15 mg twice daily. All patients had complete regression of EHIT at 6 to 25 days, and no clinically significant pulmonary embolus developed.</p><p class="headingAnchor" id="H4261918290"><span class="h2">Nerve injury</span><span class="headingEndMark"> — </span>Sensory abnormalities due to nerve injury following EVLA occur with a reported incidence ranging between &lt;1 to 7 percent [<a href="#rid60">60,108,112</a>]. Symptoms of saphenous nerve injury include pain or numbness along the medial aspect of the calf or medial foot and occasionally a feeling of pressure or tightness around the knee or ankle. These symptoms typically resolve four to six weeks after EVLA. Sural nerve injuries can cause pain or numbness in the posterior-lateral aspect of the distal third of the leg the lateral heel, ankle, and foot.</p><p>Because of the close proximity of the saphenous nerve and vein in the distal calf, saphenous nerve injury may be more likely when endovenous ablation occurs below the level of the mid-calf, due to the adherence of the saphenous nerve to the saphenous vein in the distal third of the calf [<a href="#rid13">13</a>]. (See <a class="local">'Saphenous nerve'</a> above.) </p><p>Adequate tumescent anesthesia is probably the most important factor in preventing nerve injuries. In an observational study of patients undergoing EVLA without tumescent anesthesia, the rate of paresthesia was much higher at 36 percent compared with other studies in which tumescent anesthesia was used [<a href="#rid38">38</a>].</p><p>Due to the risk for saphenous nerve injury, surgical stripping of the saphenous vein in the mid- to distal calf is no longer recommended. For similar reasons, we prefer not to extend ablation of the GSV below the mid- to upper calf. (See <a class="local">'Great saphenous vein'</a> above.)</p><p class="headingAnchor" id="H2985041048"><span class="h2">Other complications</span><span class="headingEndMark"> — </span>Other technical complications have been described in case reports. </p><p>Arteriovenous fistula formation is rare but has been reported [<a href="#rid46">46</a>]. The popliteal fossa is felt to be at increased risk for this complication following small saphenous vein ablation due to the proximity of the sural arteries to the vein and may be related to errant placement of the tumescent needle [<a href="#rid113">113,114</a>]. (See  <a class="medical medical_review" href="/z/d/html/8217.html" rel="external">"Acquired arteriovenous fistula of the lower extremity"</a>.)</p><p>Although uncommon, a retained foreign body from a broken laser catheter tip has also been reported [<a href="#rid112">112</a>]. Care in placement of the tumescent needle minimizes the potential of this complication. Device components should be examined carefully after they are removed from the patient to ensure their integrity. If there is any question about the possible loss of a device, radiographs should be obtained.<strong> </strong></p><p class="headingAnchor" id="H3117464171"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118466.html" rel="external">"Society guideline links: Chronic venous disorders"</a>.)</p><p class="headingAnchor" id="H7317558"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87610.html" rel="external">"Patient education: Vein ablation (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H715137092"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endovenous laser ablation</strong> – Endovenous laser ablation (EVLA) is a minimally invasive percutaneous technique using laser energy to ablate incompetent superficial truncal veins of the lower extremity (ie, great, small, or accessory saphenous veins). (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/8181.html" rel="external">"Overview of lower extremity chronic venous disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates</strong> – Candidates for EVLA are patients with persistent symptoms/signs of venous disease after a trial of medical therapy plus documented superficial venous reflux (ie, retrograde flow &gt;0.5 second duration) as a source of their symptoms. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure</strong> – EVLA is typically performed in an office or ambulatory surgery setting with local anesthesia and anxiolytics. If concurrent vein excision (phlebectomy) is performed, moderate sedation may be beneficial for patient comfort. Regional anesthesia is another option. (See <a class="local">'Procedure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extent of ablation</strong> – For great saphenous vein (GSV) ablation, we suggest not extending EVLA below the mid-calf to minimize the risk of saphenous nerve injury (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Symptoms of saphenous nerve injury may include pain or numbness along the medial aspect of the calf or lateral foot. These symptoms typically resolve within four to six weeks of the procedure. (See <a class="local">'Place the device sheath'</a> above and <a class="local">'Nerve injury'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pain management</strong> – Some degree of pain and/or bruising is common following EVLA, and a mild superficial phlebitis is expected. Pain associated with EVLA is usually controlled with over-the-counter pain medications (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>). Pain gradually resolves over time and is improved by wearing compression stockings. Extensive concurrent vein excision (phlebectomy) may require stronger analgesics (eg, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>). (See <a class="local">'Pain management'</a> above and <a class="local">'Patient instructions'</a> above and <a class="local">'Duration of compression therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative duplex</strong> – Duplex ultrasound should be performed within seven days of the procedure to evaluate for deep vein thrombosis and/or endovenous heat-induced thrombus (EHIT). We repeat duplex ultrasound within a week if thrombus is identified at the saphenofemoral/saphenopopliteal junction, extending up to, or into, the deep vein. (See <a class="local">'Postoperative duplex ultrasound'</a> above and <a class="local">'Endovenous heat-induced thrombus'</a> above and <a class="local">'Deep vein thrombosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">van den Bos R, Arends L, Kockaert M, et al. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009; 49:230.</a></li><li><a class="nounderline abstract_t">Darwood RJ, Gough MJ. Endovenous laser treatment for uncomplicated varicose veins. Phlebology 2009; 24 Suppl 1:50.</a></li><li><a class="nounderline abstract_t">Hoggan BL, Cameron AL, Maddern GJ. Systematic review of endovenous laser therapy versus surgery for the treatment of saphenous varicose veins. Ann Vasc Surg 2009; 23:277.</a></li><li><a class="nounderline abstract_t">Kalteis M, Berger I, Messie-Werndl S, et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study. J Vasc Surg 2008; 47:822.</a></li><li><a class="nounderline abstract_t">Rasmussen L, Lawaetz M, Bjoern L, et al. Randomized clinical trial comparing endovenous laser ablation and stripping of the great saphenous vein with clinical and duplex outcome after 5 years. J Vasc Surg 2013; 58:421.</a></li><li><a class="nounderline abstract_t">Christenson JT, Gueddi S, Gemayel G, Bounameaux H. Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. J Vasc Surg 2010; 52:1234.</a></li><li><a class="nounderline abstract_t">Ravi R, Rodriguez-Lopez JA, Trayler EA, et al. Endovenous ablation of incompetent saphenous veins: a large single-center experience. J Endovasc Ther 2006; 13:244.</a></li><li><a class="nounderline abstract_t">Prakash, Kumari J, Nishanth Reddy N, et al. A review of literature along with a cadaveric study of the prevalence of the Giacomini vein (the thigh extension of the small saphenous vein) in the Indian population. Rom J Morphol Embryol 2008; 49:537.</a></li><li><a class="nounderline abstract_t">Gibson KD, Ferris BL, Polissar N, et al. Endovenous laser treatment of the small [corrected] saphenous vein: efficacy and complications. J Vasc Surg 2007; 45:795.</a></li><li><a class="nounderline abstract_t">Delis KT, Knaggs AL, Khodabakhsh P. Prevalence, anatomic patterns, valvular competence, and clinical significance of the Giacomini vein. J Vasc Surg 2004; 40:1174.</a></li><li><a class="nounderline abstract_t">Schweighofer G, Mühlberger D, Brenner E. The anatomy of the small saphenous vein: fascial and neural relations, saphenofemoral junction, and valves. J Vasc Surg 2010; 51:982.</a></li><li><a class="nounderline abstract_t">Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg 2002; 36:416.</a></li><li><a class="nounderline abstract_t">Dayan V, Cura L, Cubas S, Carriquiry G. Surgical anatomy of the saphenous nerve. Ann Thorac Surg 2008; 85:896.</a></li><li><a class="nounderline abstract_t">Kerver AL, van der Ham AC, Theeuwes HP, et al. The surgical anatomy of the small saphenous vein and adjacent nerves in relation to endovenous thermal ablation. J Vasc Surg 2012; 56:181.</a></li><li><a class="nounderline abstract_t">Rodriguez-Acevedo O, Elstner K, Zea A, et al. The sural nerve: Sonographic anatomy, variability and relation to the small saphenous vein in the setting of endovenous thermal ablation. Phlebology 2017; 32:49.</a></li><li><a class="nounderline abstract_t">Brown CS, Osborne NH, Kim GY, et al. Comparison of unilateral vs bilateral and staged bilateral vs concurrent bilateral truncal endovenous ablation in the Vascular Quality Initiative. J Vasc Surg Venous Lymphat Disord 2021; 9:113.</a></li><li><a class="nounderline abstract_t">Wright TF, Brunetti GF, Kennedy P. Lidocaine safety after saphenous vein tumescent anesthesia. Phlebology 2019; 34:683.</a></li><li><a class="nounderline abstract_t">Holt NF. Tumescent anaesthesia: its applications and well tolerated use in the out-of-operating room setting. Curr Opin Anaesthesiol 2017; 30:518.</a></li><li><a class="nounderline abstract_t">Gohel MS, Heatley F, Liu X, et al. A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. N Engl J Med 2018; 378:2105.</a></li><li><a class="nounderline abstract_t">Nelzén O, Fransson I, Swedish SEPS Study Group. Early results from a randomized trial of saphenous surgery with or without subfascial endoscopic perforator surgery in patients with a venous ulcer. Br J Surg 2011; 98:495.</a></li><li><a class="nounderline abstract_t">Schoonover JP, King JT, Gray C, et al. 3 alternatives to standard varicose vein treatment. J Fam Pract 2009; 58:522.</a></li><li><a class="nounderline abstract_t">Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370:1307.</a></li><li><a class="nounderline abstract_t">Monahan DL. Can phlebectomy be deferred in the treatment of varicose veins? J Vasc Surg 2005; 42:1145.</a></li><li><a class="nounderline abstract_t">Welch HJ. Endovenous ablation of the great saphenous vein may avert phlebectomy for branch varicose veins. J Vasc Surg 2006; 44:601.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Gough MJ. Influence of warfarin on the success of endovenous laser ablation (EVLA) of the great saphenous vein (GSV). Eur J Vasc Endovasc Surg 2009; 38:506.</a></li><li><a class="nounderline abstract_t">Riesenman PJ, de Fritas DJ, Konigsberg SG, Kasirajan K. Noninterruption of warfarin therapy is safe and does not compromise outcome in patients undergoing endovenous laser therapy (EVLT). Vasc Endovascular Surg 2011; 45:524.</a></li><li><a class="nounderline abstract_t">Sharifi M, Mehdipour M, Bay C, et al. Effect of anticoagulation on endothermal ablation of the great saphenous vein. J Vasc Surg 2011; 53:147.</a></li><li><a class="nounderline abstract_t">Gabriel V, Jimenez JC, Alktaifi A, et al. Success of endovenous saphenous and perforator ablation in patients with symptomatic venous insufficiency receiving long-term warfarin therapy. Ann Vasc Surg 2012; 26:607.</a></li><li><a class="nounderline abstract_t">Chang H, Sadek M, Barfield ME, et al. Direct oral anticoagulant agents might be safe for patients undergoing endovenous radiofrequency and laser ablation. J Vasc Surg Venous Lymphat Disord 2023; 11:25.</a></li><li><a class="nounderline abstract_t">Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.</a></li><li><a class="nounderline abstract_t">Kabnick LS, Sadek M, Bjarnason H, et al. Classification and treatment of endothermal heat-induced thrombosis: Recommendations from the American Venous Forum and the Society for Vascular Surgery. J Vasc Surg Venous Lymphat Disord 2021; 9:6.</a></li><li><a class="nounderline abstract_t">Schmedt CG, Sroka R, Steckmeier S, et al. Investigation on radiofrequency and laser (980 nm) effects after endoluminal treatment of saphenous vein insufficiency in an ex-vivo model. Eur J Vasc Endovasc Surg 2006; 32:318.</a></li><li><a class="nounderline abstract_t">Proebstle TM, Sandhofer M, Kargl A, et al. Thermal damage of the inner vein wall during endovenous laser treatment: key role of energy absorption by intravascular blood. Dermatol Surg 2002; 28:596.</a></li><li><a class="nounderline abstract_t">Mordon SR, Wassmer B, Zemmouri J. Mathematical modeling of endovenous laser treatment (ELT). Biomed Eng Online 2006; 5:26.</a></li><li><a class="nounderline abstract_t">Disselhoff BC, Rem AI, Verdaasdonk RM, et al. Endovenous laser ablation: an experimental study on the mechanism of action. Phlebology 2008; 23:69.</a></li><li><a class="nounderline abstract_t">Starodubtsev V, Lukyanenko M, Karpenko A, Ignatenko P. Endovenous laser ablation in patients with wide diameter of the proximal segment of the great saphenous vein: Comparison of methods. Phlebology 2015; 30:700.</a></li><li><a class="nounderline abstract_t">Kabnick LS. Outcome of different endovenous laser wavelengths for great saphenous vein ablation. J Vasc Surg 2006; 43:88.</a></li><li><a class="nounderline abstract_t">Chang CJ, Chua JJ. Endovenous laser photocoagulation (EVLP) for varicose veins. Lasers Surg Med 2002; 31:257.</a></li><li><a class="nounderline abstract_t">Doganci S, Demirkilic U. Comparison of 980 nm laser and bare-tip fibre with 1470 nm laser and radial fibre in the treatment of great saphenous vein varicosities: a prospective randomised clinical trial. Eur J Vasc Endovasc Surg 2010; 40:254.</a></li><li><a class="nounderline abstract_t">Malskat WS, Giang J, De Maeseneer MG, et al. Randomized clinical trial of 940- versus 1470-nm endovenous laser ablation for great saphenous vein incompetence. Br J Surg 2016; 103:192.</a></li><li><a class="nounderline abstract_t">Kabnick LS, Sadek M. Fiber type as compared to wavelength may contribute more to improving postoperative recovery following endovenous laser ablation. J Vasc Surg Venous Lymphat Disord 2016; 4:286.</a></li><li><a class="nounderline abstract_t">Hirokawa M, Kurihara N. Comparison of Bare-Tip and Radial Fiber in Endovenous Laser Ablation with 1470 nm Diode Laser. Ann Vasc Dis 2014; 7:239.</a></li><li><a class="nounderline abstract_t">Vuylsteke ME, Thomis S, Mahieu P, et al. Endovenous laser ablation of the great saphenous vein using a bare fibre versus a tulip fibre: a randomised clinical trial. Eur J Vasc Endovasc Surg 2012; 44:587.</a></li><li><a class="nounderline abstract_t">Hamel-Desnos C, Gérard JL, Desnos P. Endovenous laser procedure in a clinic room: feasibility and side effects study of 1,700 cases. Phlebology 2009; 24:125.</a></li><li><a class="nounderline abstract_t">Hurmerinta-Kurkijärvi O, Weselius EM, Halmesmäki K, et al. Femoral nerve blockade during endovenous laser ablation of great saphenous vein decreases pain but does not affect the use of opioids during the procedure. J Vasc Surg Venous Lymphat Disord 2023; 11:921.</a></li><li><a class="nounderline abstract_t">Rudarakanchana N, Berland TL, Chasin C, et al. Arteriovenous fistula after endovenous ablation for varicose veins. J Vasc Surg 2012; 55:1492.</a></li><li><a class="nounderline abstract_t">Klein JA, Jeske DR. Estimated Maximal Safe Dosages of Tumescent Lidocaine. Anesth Analg 2016; 122:1350.</a></li><li><a class="nounderline abstract_t">Shoab SS, Lowry D, Tiwari A. Effect of treated length in endovenous laser ablation of great saphenous vein on early outcomes. J Vasc Surg Venous Lymphat Disord 2016; 4:416.</a></li><li><a class="nounderline abstract_t">Carradice D, Mekako AI, Hatfield J, Chetter IC. Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins. Br J Surg 2009; 96:369.</a></li><li><a class="nounderline abstract_t">El-Sheikha J, Nandhra S, Carradice D, et al. Clinical outcomes and quality of life 5 years after a randomized trial of concomitant or sequential phlebectomy following endovenous laser ablation for varicose veins. Br J Surg 2014; 101:1093.</a></li><li><a class="nounderline abstract_t">Schanzer H. Endovenous ablation plus microphlebectomy/sclerotherapy for the treatment of varicose veins: single or two-stage procedure? Vasc Endovascular Surg 2010; 44:545.</a></li><li><a class="nounderline abstract_t">Kokkosis AA, Schanzer H. Anatomical and clinical factors favoring the performance of saphenous ablation and microphlebectomy or sclerotherapy as a single-stage procedure. Phlebology 2015; 30:627.</a></li><li><a class="nounderline abstract_t">El-Sheikha J, Nandhra S, Carradice D, et al. Compression regimes after endovenous ablation for superficial venous insufficiency--A survey of members of the Vascular Society of Great Britain and Ireland. Phlebology 2016; 31:16.</a></li><li><a class="nounderline abstract_t">El-Sheikha J, Carradice D, Nandhra S, et al. Systematic review of compression following treatment for varicose veins. Br J Surg 2015; 102:719.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above- and below-knee reflux? A randomized controlled trial. J Vasc Surg 2008; 48:173.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Darwood RJ, Dellagrammaticas D, et al. The clinical significance of below-knee great saphenous vein reflux following endovenous laser ablation of above-knee great saphenous vein. Phlebology 2009; 24:17.</a></li><li><a class="nounderline abstract_t">Doganci S, Yildirim V, Demirkilic U. Does puncture site affect the rate of nerve injuries following endovenous laser ablation of the small saphenous veins? Eur J Vasc Endovasc Surg 2011; 41:400.</a></li><li><a class="nounderline abstract_t">de Medeiros CA, Luccas GC. Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins. Dermatol Surg 2005; 31:1685.</a></li><li><a class="nounderline abstract_t">Puggioni A, Kalra M, Carmo M, et al. Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: analysis of early efficacy and complications. J Vasc Surg 2005; 42:488.</a></li><li><a class="nounderline abstract_t">Desmyttère J, Grard C, Wassmer B, Mordon S. Endovenous 980-nm laser treatment of saphenous veins in a series of 500 patients. J Vasc Surg 2007; 46:1242.</a></li><li><a class="nounderline abstract_t">Gornik HL, Gerhard-Herman MD, Misra S, et al. ACCF/ACR/AIUM/ASE/IAC/SCAI/SCVS/SIR/SVM/SVS/SVU 2013 appropriate use criteria for peripheral vascular ultrasound and physiological testing part II: testing for venous disease and evaluation of hemodialysis access: a report of the american college of cardiology foundation appropriate use criteria task force. J Am Coll Cardiol 2013; 62:649.</a></li><li><a class="nounderline abstract_t">Kim HS, Paxton BE. Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments. J Vasc Interv Radiol 2006; 17:1449.</a></li><li><a class="nounderline abstract_t">Kemaloğlu C. Saphenous vein diameter is a single risk factor for early recanalization after endothermal ablation of incompetent great saphenous vein. Vascular 2019; 27:537.</a></li><li><a class="nounderline abstract_t">Darwood RJ, Theivacumar N, Dellagrammaticas D, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg 2008; 95:294.</a></li><li><a class="nounderline abstract_t">Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomised clinical trial comparing endovenous laser ablation with stripping of the great saphenous vein: clinical outcome and recurrence after 2 years. Eur J Vasc Endovasc Surg 2010; 39:630.</a></li><li><a class="nounderline abstract_t">Agus GB, Mancini S, Magi G, IEWG. The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period. Int Angiol 2006; 25:209.</a></li><li><a class="nounderline abstract_t">Ravi R, Trayler EA, Barrett DA, Diethrich EB. Endovenous thermal ablation of superficial venous insufficiency of the lower extremity: single-center experience with 3000 limbs treated in a 7-year period. J Endovasc Ther 2009; 16:500.</a></li><li><a class="nounderline abstract_t">Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol 2003; 14:991.</a></li><li><a class="nounderline abstract_t">Flessenkämper I, Hartmann M, Hartmann K, et al. Endovenous laser ablation with and without high ligation compared to high ligation and stripping for treatment of great saphenous varicose veins: Results of a multicentre randomised controlled trial with up to 6 years follow-up. Phlebology 2016; 31:23.</a></li><li><a class="nounderline abstract_t">Wallace T, El-Sheikha J, Nandhra S, et al. Long-term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins. Br J Surg 2018; 105:1759.</a></li><li><a class="nounderline abstract_t">Gauw SA, Lawson JA, van Vlijmen-van Keulen CJ, et al. Five-year follow-up of a randomized, controlled trial comparing saphenofemoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anesthesia. J Vasc Surg 2016; 63:420.</a></li><li><a class="nounderline abstract_t">Rass K, Frings N, Glowacki P, et al. Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study). Arch Dermatol 2012; 148:49.</a></li><li><a class="nounderline abstract_t">Chaar CI, Hirsch SA, Cwenar MT, et al. Expanding the role of endovenous laser therapy: results in large diameter saphenous, small saphenous, and anterior accessory veins. Ann Vasc Surg 2011; 25:656.</a></li><li><a class="nounderline abstract_t">Florescu C, Curry G, Buckenham T. Role of endovenous laser therapy in large and very large diameter great saphenous veins. ANZ J Surg 2016; 86:608.</a></li><li><a class="nounderline abstract_t">Atasoy MM. Efficacy and Safety of Endovenous Laser Ablation in Very Large and Tortuous Great Saphenous Veins. J Vasc Interv Radiol 2015; 26:1347.</a></li><li><a class="nounderline abstract_t">Bush RG, Hammond K. Treatment of incompetent vein of Giacomini (thigh extension branch). Ann Vasc Surg 2007; 21:245.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation (EVLA) of great saphenous vein to abolish "paradoxical reflux" in the Giacomini vein: a short report. Eur J Vasc Endovasc Surg 2007; 34:229.</a></li><li><a class="nounderline abstract_t">Nwaejike N, Srodon PD, Kyriakides C. Endovenous laser ablation for short saphenous vein incompetence. Ann Vasc Surg 2009; 23:39.</a></li><li><a class="nounderline abstract_t">Trip-Hoving M, Verheul JC, van Sterkenburg SM, et al. Endovenous laser therapy of the small saphenous vein: patient satisfaction and short-term results. Photomed Laser Surg 2009; 27:655.</a></li><li><a class="nounderline abstract_t">Theivacumar NS, Darwood RJ, Gough MJ. Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein. Eur J Vasc Endovasc Surg 2009; 37:477.</a></li><li><a class="nounderline abstract_t">Kontothanassis D, Di Mitri R, Ferrari Ruffino S, et al. Endovenous laser treatment of the small saphenous vein. J Vasc Surg 2009; 49:973.</a></li><li><a class="nounderline abstract_t">Monahan TS, Belek K, Sarkar R. Results of radiofrequency ablation of the small saphenous vein in the supine position. Vasc Endovascular Surg 2012; 46:40.</a></li><li><a class="nounderline abstract_t">She W, Dai Y, Du X, et al. Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2010; 142:266.</a></li><li><a class="nounderline abstract_t">Proebstle TM, Herdemann S. Early results and feasibility of incompetent perforator vein ablation by endovenous laser treatment. Dermatol Surg 2007; 33:162.</a></li><li><a class="nounderline abstract_t">Ozkan U. Endovenous laser ablation of incompetent perforator veins: a new technique in treatment of chronic venous disease. Cardiovasc Intervent Radiol 2009; 32:1067.</a></li><li><a class="nounderline abstract_t">Park SW, Hwang JJ, Yun IJ, et al. Randomized clinical trial comparing two methods for endovenous laser ablation of incompetent perforator veins in thigh and great saphenous vein without evidence of saphenofemoral reflux. Dermatol Surg 2012; 38:640.</a></li><li><a class="nounderline abstract_t">Shepherd AC, Gohel MS, Brown LC, et al. Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins. Br J Surg 2010; 97:810.</a></li><li><a class="nounderline abstract_t">Pronk P, Gauw SA, Mooij MC, et al. Randomised controlled trial comparing sapheno-femoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anaesthesia: one year results. Eur J Vasc Endovasc Surg 2010; 40:649.</a></li><li><a class="nounderline abstract_t">Carradice D, Mekako AI, Mazari FA, et al. Randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins. Br J Surg 2011; 98:501.</a></li><li><a class="nounderline abstract_t">Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg 2007; 46:308.</a></li><li><a class="nounderline abstract_t">Samuel N, Carradice D, Wallace T, et al. Randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varicose veins. Ann Surg 2013; 257:419.</a></li><li><a class="nounderline abstract_t">Dunst KM, Huemer GM, Wayand W, Shamiyeh A. Diffuse phlegmonous phlebitis after endovenous laser treatment of the greater saphenous vein. J Vasc Surg 2006; 43:1056.</a></li><li><a class="nounderline abstract_t">Kane K, Fisher T, Bennett M, et al. The incidence and outcome of endothermal heat-induced thrombosis after endovenous laser ablation. Ann Vasc Surg 2014; 28:1744.</a></li><li><a class="nounderline abstract_t">Carruthers TN, Farber A, Rybin D, et al. Interventions on the superficial venous system for chronic venous insufficiency by surgeons in the modern era: an analysis of ACS-NSQIP. Vasc Endovascular Surg 2014; 48:482.</a></li><li><a class="nounderline abstract_t">Merchant RF, Pichot O, Closure Study Group. Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency. J Vasc Surg 2005; 42:502.</a></li><li><a class="nounderline abstract_t">Lawrence PF, Chandra A, Wu M, et al. Classification of proximal endovenous closure levels and treatment algorithm. J Vasc Surg 2010; 52:388.</a></li><li class="breakAll">Kabnick LS. Thrombus at the SFJ after endovenous ablation: What should I do now? Third International Vein Congress: In-office Techniques. Miami, FL 2005.</li><li><a class="nounderline abstract_t">Rhee SJ, Cantelmo NL, Conrad MF, Stoughton J. Factors influencing the incidence of endovenous heat-induced thrombosis (EHIT). Vasc Endovascular Surg 2013; 47:207.</a></li><li><a class="nounderline abstract_t">Marsh P, Price BA, Holdstock J, et al. Deep vein thrombosis (DVT) after venous thermoablation techniques: rates of endovenous heat-induced thrombosis (EHIT) and classical DVT after radiofrequency and endovenous laser ablation in a single centre. Eur J Vasc Endovasc Surg 2010; 40:521.</a></li><li><a class="nounderline abstract_t">Knipp BS, Blackburn SA, Bloom JR, et al. Endovenous laser ablation: venous outcomes and thrombotic complications are independent of the presence of deep venous insufficiency. J Vasc Surg 2008; 48:1538.</a></li><li><a class="nounderline abstract_t">Haqqani OP, Vasiliu C, O'Donnell TF, Iafrati MD. Great saphenous vein patency and endovenous heat-induced thrombosis after endovenous thermal ablation with modified catheter tip positioning. J Vasc Surg 2011; 54:10S.</a></li><li><a class="nounderline abstract_t">Ryer EJ, Elmore JR, Garvin RP, et al. Value of delayed duplex ultrasound assessment after endothermal ablation of the great saphenous vein. J Vasc Surg 2016; 64:446.</a></li><li><a class="nounderline abstract_t">Chi YW, Woods TC. Clinical risk factors to predict deep venous thrombosis post-endovenous laser ablation of saphenous veins. Phlebology 2014; 29:150.</a></li><li><a class="nounderline abstract_t">Benarroch-Gampel J, Sheffield KM, Boyd CA, et al. Analysis of venous thromboembolic events after saphenous ablation. J Vasc Surg Venous Lymphat Disord 2013; 1:26.</a></li><li><a class="nounderline abstract_t">Skeik N, Zimmerman KP, Tretinyak AS, et al. The success and safety of endovenous ablation in patients with previous superficial venous thrombosis: a retrospective case-control study. Vasc Endovascular Surg 2013; 47:353.</a></li><li><a class="nounderline abstract_t">Lin JC, Peterson EL, Rivera ML, et al. Vein mapping prior to endovenous catheter ablation of the great saphenous vein predicts risk of endovenous heat-induced thrombosis. Vasc Endovascular Surg 2012; 46:378.</a></li><li><a class="nounderline abstract_t">Sadek M, Kabnick LS, Rockman CB, et al. Increasing the distance peripheral to the saphenofemoral junction may result in a diminished rate of endothermal heat-induced thrombosis. J Vasc Surg Venous Lymphat Disord 2014; 1:257.</a></li><li><a class="nounderline abstract_t">Nwaejike N, Srodon PD, Kyriakides C. 5-years of endovenous laser ablation (EVLA) for the treatment of varicose veins--a prospective study. Int J Surg 2009; 7:347.</a></li><li><a class="nounderline abstract_t">Healy DA, Kimura S, Power D, et al. A Systematic Review and Meta-analysis of Thrombotic Events Following Endovenous Thermal Ablation of the Great Saphenous Vein. Eur J Vasc Endovasc Surg 2018; 56:410.</a></li><li><a class="nounderline abstract_t">Caggiati A, Franceschini M. Stroke following endovenous laser treatment of varicose veins. J Vasc Surg 2010; 51:218.</a></li><li><a class="nounderline abstract_t">Fokin AA, Borsuk DA, Kazachkov EL. [Efficacy of using rivaroxaban for treatment of heat-induced thrombosis after endovenous laser ablation]. Angiol Sosud Khir 2016; 22:97.</a></li><li><a class="nounderline abstract_t">Van Den Bos RR, Neumann M, De Roos KP, Nijsten T. Endovenous laser ablation-induced complications: review of the literature and new cases. Dermatol Surg 2009; 35:1206.</a></li><li><a class="nounderline abstract_t">Timperman PE. Arteriovenous fistula after endovenous laser treatment of the short saphenous vein. J Vasc Interv Radiol 2004; 15:625.</a></li><li><a class="nounderline abstract_t">Vaz C, Matos A, Oliveira J, et al. Iatrogenic arteriovenous fistula following endovenous laser therapy of the short saphenous vein. Ann Vasc Surg 2009; 23:412.e15.</a></li></ol></div><div id="topicVersionRevision">Topic 15198 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692348" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Endovenous therapies of lower extremity varicosities: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307441" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Endovenous laser treatment for uncomplicated varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128927" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systematic review of endovenous laser therapy versus surgery for the treatment of saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295441" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23768792" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Randomized clinical trial comparing endovenous laser ablation and stripping of the great saphenous vein with clinical and duplex outcome after 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20801608" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16643080" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Endovenous ablation of incompetent saphenous veins: a large single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050803" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A review of literature along with a cadaveric study of the prevalence of the Giacomini vein (the thigh extension of the small saphenous vein) in the Indian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306952" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Endovenous laser treatment of the small [corrected] saphenous vein: efficacy and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622372" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence, anatomic patterns, valvular competence, and clinical significance of the Giacomini vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20022210" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The anatomy of the small saphenous vein: fascial and neural relations, saphenofemoral junction, and valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12170230" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291167" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Surgical anatomy of the saphenous nerve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503186" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The surgical anatomy of the small saphenous vein and adjacent nerves in relation to endovenous thermal ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826266" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The sural nerve: Sonographic anatomy, variability and relation to the small saphenous vein in the setting of endovenous thermal ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32470615" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of unilateral vs bilateral and staged bilateral vs concurrent bilateral truncal endovenous ablation in the Vascular Quality Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30871437" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lidocaine safety after saphenous vein tumescent anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509770" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tumescent anaesthesia: its applications and well tolerated use in the out-of-operating room setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688123" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A Randomized Trial of Early Endovenous Ablation in Venous Ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21656715" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early results from a randomized trial of saphenous surgery with or without subfascial endoscopic perforator surgery in patients with a venous ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874730" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 3 alternatives to standard varicose vein treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24524551" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk of a thrombotic event after the 6-week postpartum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376206" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Can phlebectomy be deferred in the treatment of varicose veins?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950441" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Endovenous ablation of the great saphenous vein may avert phlebectomy for branch varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577490" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Influence of warfarin on the success of endovenous laser ablation (EVLA) of the great saphenous vein (GSV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21715419" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Noninterruption of warfarin therapy is safe and does not compromise outcome in patients undergoing endovenous laser therapy (EVLT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864301" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of anticoagulation on endothermal ablation of the great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516240" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Success of endovenous saphenous and perforator ablation in patients with symptomatic venous insufficiency receiving long-term warfarin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35872143" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Direct oral anticoagulant agents might be safe for patients undergoing endovenous radiofrequency and laser ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23327981" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical practice guidelines for antimicrobial prophylaxis in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33012690" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Classification and treatment of endothermal heat-induced thrombosis: Recommendations from the American Venous Forum and the Society for Vascular Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781172" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Investigation on radiofrequency and laser (980 nm) effects after endoluminal treatment of saphenous vein insufficiency in an ex-vivo model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135514" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thermal damage of the inner vein wall during endovenous laser treatment: key role of energy absorption by intravascular blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638133" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mathematical modeling of endovenous laser treatment (ELT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18453482" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endovenous laser ablation: an experimental study on the mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305462" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endovenous laser ablation in patients with wide diameter of the proximal segment of the great saphenous vein: Comparison of methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414394" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outcome of different endovenous laser wavelengths for great saphenous vein ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355571" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endovenous laser photocoagulation (EVLP) for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547079" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of 980 nm laser and bare-tip fibre with 1470 nm laser and radial fibre in the treatment of great saphenous vein varicosities: a prospective randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26661521" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Randomized clinical trial of 940- versus 1470-nm endovenous laser ablation for great saphenous vein incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27318047" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fiber type as compared to wavelength may contribute more to improving postoperative recovery following endovenous laser ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25298824" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of Bare-Tip and Radial Fiber in Endovenous Laser Ablation with 1470 nm Diode Laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084274" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Endovenous laser ablation of the great saphenous vein using a bare fibre versus a tulip fibre: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470864" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Endovenous laser procedure in a clinic room: feasibility and side effects study of 1,700 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37142055" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Femoral nerve blockade during endovenous laser ablation of great saphenous vein decreases pain but does not affect the use of opioids during the procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22119247" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Arteriovenous fistula after endovenous ablation for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26895001" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Estimated Maximal Safe Dosages of Tumescent Lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27638994" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of treated length in endovenous laser ablation of great saphenous vein on early outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19283745" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916467" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical outcomes and quality of life 5 years after a randomized trial of concomitant or sequential phlebectomy following endovenous laser ablation for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675329" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Endovenous ablation plus microphlebectomy/sclerotherapy for the treatment of varicose veins: single or two-stage procedure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25300313" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anatomical and clinical factors favoring the performance of saphenous ablation and microphlebectomy or sclerotherapy as a single-stage procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589597" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Compression regimes after endovenous ablation for superficial venous insufficiency--A survey of members of the Vascular Society of Great Britain and Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25833417" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Systematic review of compression following treatment for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440756" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above- and below-knee reflux? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155336" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The clinical significance of below-knee great saphenous vein reflux following endovenous laser ablation of above-knee great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21194988" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Does puncture site affect the rate of nerve injuries following endovenous laser ablation of the small saphenous veins?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336888" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171593" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: analysis of early efficacy and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18155001" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Endovenous 980-nm laser treatment of saphenous veins in a series of 500 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23876422" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ACCF/ACR/AIUM/ASE/IAC/SCAI/SCVS/SIR/SVM/SVS/SVU 2013 appropriate use criteria for peripheral vascular ultrasound and physiological testing part II: testing for venous disease and evaluation of hemodialysis access: a report of the american college of cardiology foundation appropriate use criteria task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16990464" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30880609" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Saphenous vein diameter is a single risk factor for early recanalization after endothermal ablation of incompetent great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278775" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20064730" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Randomised clinical trial comparing endovenous laser ablation with stripping of the great saphenous vein: clinical outcome and recurrence after 2 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763541" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19702351" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Endovenous thermal ablation of superficial venous insufficiency of the lower extremity: single-center experience with 3000 limbs treated in a 7-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902556" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Endovenous laser treatment of saphenous vein reflux: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25342648" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Endovenous laser ablation with and without high ligation compared to high ligation and stripping for treatment of great saphenous varicose veins: Results of a multicentre randomised controlled trial with up to 6 years follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30132797" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term outcomes of endovenous laser ablation and conventional surgery for great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602795" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Five-year follow-up of a randomized, controlled trial comparing saphenofemoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21931012" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21724104" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Expanding the role of endovenous laser therapy: results in large diameter saphenous, small saphenous, and anterior accessory veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845915" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Role of endovenous laser therapy in large and very large diameter great saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26065928" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy and Safety of Endovenous Laser Ablation in Very Large and Tortuous Great Saphenous Veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349373" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of incompetent vein of Giacomini (thigh extension branch).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331749" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Endovenous laser ablation (EVLA) of great saphenous vein to abolish "paradoxical reflux" in the Giacomini vein: a short report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18619773" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Endovenous laser ablation for short saphenous vein incompetence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580364" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Endovenous laser therapy of the small saphenous vein: patient satisfaction and short-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201621" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341887" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Endovenous laser treatment of the small saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156157" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Results of radiofrequency ablation of the small saphenous vein in the supine position.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20115986" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300601" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Early results and feasibility of incompetent perforator vein ablation by endovenous laser treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609603" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endovenous laser ablation of incompetent perforator veins: a new technique in treatment of chronic venous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22211402" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Randomized clinical trial comparing two methods for endovenous laser ablation of incompetent perforator veins in thigh and great saphenous vein without evidence of saphenofemoral reflux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20473992" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Randomized clinical trial of VNUS ClosureFAST radiofrequency ablation versus laser for varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888274" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Randomised controlled trial comparing sapheno-femoral ligation and stripping of the great saphenous vein with endovenous laser ablation (980 nm) using local tumescent anaesthesia: one year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21283981" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Randomized clinical trial of endovenous laser ablation compared with conventional surgery for great saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17600655" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160149" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Randomized clinical trial of endovenous laser ablation versus conventional surgery for small saphenous varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678705" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Diffuse phlegmonous phlebitis after endovenous laser treatment of the greater saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24911803" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The incidence and outcome of endothermal heat-induced thrombosis after endovenous laser ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487248" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Interventions on the superficial venous system for chronic venous insufficiency by surgeons in the modern era: an analysis of ACS-NSQIP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171596" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20646894" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Classification of proximal endovenous closure levels and treatment algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20646894" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Classification of proximal endovenous closure levels and treatment algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23427285" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Factors influencing the incidence of endovenous heat-induced thrombosis (EHIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20655773" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Deep vein thrombosis (DVT) after venous thermoablation techniques: rates of endovenous heat-induced thrombosis (EHIT) and classical DVT after radiofrequency and endovenous laser ablation in a single centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18829223" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Endovenous laser ablation: venous outcomes and thrombotic complications are independent of the presence of deep venous insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22032880" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Great saphenous vein patency and endovenous heat-induced thrombosis after endovenous thermal ablation with modified catheter tip positioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26906977" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Value of delayed duplex ultrasound assessment after endothermal ablation of the great saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23434616" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Clinical risk factors to predict deep venous thrombosis post-endovenous laser ablation of saphenous veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26993890" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Analysis of venous thromboembolic events after saphenous ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23640474" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The success and safety of endovenous ablation in patients with previous superficial venous thrombosis: a retrospective case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22649164" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Vein mapping prior to endovenous catheter ablation of the great saphenous vein predicts risk of endovenous heat-induced thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Increasing the distance peripheral to the saphenofemoral junction may result in a diminished rate of endothermal heat-induced thrombosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19446660" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : 5-years of endovenous laser ablation (EVLA) for the treatment of varicose veins--a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29895399" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A Systematic Review and Meta-analysis of Thrombotic Events Following Endovenous Thermal Ablation of the Great Saphenous Vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782516" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Stroke following endovenous laser treatment of varicose veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27935887" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : [Efficacy of using rivaroxaban for treatment of heat-induced thrombosis after endovenous laser ablation].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19469796" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Endovenous laser ablation-induced complications: review of the literature and new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178724" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Arteriovenous fistula after endovenous laser treatment of the short saphenous vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973984" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Iatrogenic arteriovenous fistula following endovenous laser therapy of the short saphenous vein.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
